Search

Your search keyword '"Sandhu, Karamjeet"' showing total 172 results
Start Over Author "Sandhu, Karamjeet" Language english
172 results on '"Sandhu, Karamjeet"'

1. Impact of spliceosome mutation on outcomes of myelodysplastic syndrome and chronic myelomonocytic leukemia patients undergoing allogeneic hematopoietic cell transplantation

Author

Desai, Amrita, Samara, Yazeed, Yang, Dongyun, Ball, Brian, Braun, Adam, Koller, Paul, Blackmon, Amanda, Agrawal, Vaibhav, Pourhassan, Hoda, Amanam, Idoroenyi, Arslan, Shukaib, Otoukesh, Salman, Sandhu, Karamjeet, Aldoss, Ibrahim, Ali, Haris, Salhotra, Amandeep, Al Malki, Monzr M., Artz, Andrew, Becker, Pamela, Smith, Eileen, Stein, Anthony, Marcucci, Guido, Forman, Stephen J., Curtin, Peter, Nakamura, Ryotaro, and Pullarkat, Vinod

Published
2024
Full Text
View/download PDF

2. Incidence, clinical presentation, risk factors, outcomes, and biomarkers in de novo late acute GVHD

Author

Akahoshi, Yu, Spyrou, Nikolaos, Hogan, William J., Ayuk, Francis, DeFilipp, Zachariah, Weber, Daniela, Choe, Hannah K., Hexner, Elizabeth O., Rösler, Wolf, Etra, Aaron M., Sandhu, Karamjeet, Yanik, Gregory A., Chanswangphuwana, Chantiya, Kitko, Carrie L., Reshef, Ran, Kraus, Sabrina, Wölfl, Matthias, Eder, Matthias, Bertrand, Hannah, Qayed, Muna, Merli, Pietro, Grupp, Stephan A., Aguayo-Hiraldo, Paibel, Schechter, Tal, Ullrich, Evelyn, Baez, Janna, Beheshti, Rahnuma, Gleich, Sigrun, Kowalyk, Steven, Morales, George, Young, Rachel, Kwon, Deukwoo, Nakamura, Ryotaro, Levine, John E., Ferrara, James L. M., and Chen, Yi-Bin

Published
2023
Full Text
View/download PDF

3. Association of pre-transplant vancomycin resistant enterococcus colonization status on long-term outcomes of allogeneic-hematopoietic cell transplantation

Author

Salhotra, Amandeep, Sandhu, Karamjeet S., Yang, Dongyun, Mokhtari, Sally, O’Hearn, James, Tegtmeier, Bernard, Al Malki, Monzr M., Abella, Justine, Meguro, Akemi, Dickter, Jana, Khambapati, Swetha, Spielberger, Ricardo, Artz, Andrew, Forman, Stephen J., Smith, Eileen, Nakamura, Ryotaro, and Dadwal, Sanjeet S.

Published
2023
Full Text
View/download PDF

4. Post-Transplantation Sinusoidal Obstruction Syndrome in Adult Patients with B Cell Acute Lymphoblastic Leukemia Treated with Pretransplantation Inotuzumab

Author

Agrawal, Vaibhav, Pourhassan, Hoda, Tsai, Ni-Chun, Ngo, Dat, Koller, Paul, Malki, Monzr M. Al, Salhotra, Amandeep, Ali, Haris, Aribi, Ahmed, Sandhu, Karamjeet S., Arslan, Shukaib, Ball, Brian, Otoukesh, Salman, Amanam, Idoroenyi, Artz, Andrew, Singh, Dupinder, Becker, Pamela S., Stewart, Forrest M., Smith, Eileen P., Curtin, Peter, Stein, Anthony S., Marcucci, Guido, Forman, Stephen J., Nakamura, Ryotaro, Pullarkat, Vinod, and Aldoss, Ibrahim

Published
2023
Full Text
View/download PDF

5. A phase 2 study of interleukin-22 and systemic corticosteroids as initial treatment for acute GVHD of the lower GI tract

Author

Ponce, Doris M., Alousi, Amin M., Nakamura, Ryotaro, Slingerland, John, Calafiore, Marco, Sandhu, Karamjeet S., Barker, Juliet N., Devlin, Sean, Shia, Jinru, Giralt, Sergio, Perales, Miguel-Angel, Moore, Gillian, Fatmi, Samira, Soto, Cristina, Gomes, Antonio, Giardina, Paul, Marcello, LeeAnn, Yan, Xiaoqiang, Tang, Tom, Dreyer, Kevin, Chen, Jianmin, Daley, William L., Peled, Jonathan U., van den Brink, Marcel R. M., and Hanash, Alan M.

Published
2023
Full Text
View/download PDF

6. Consolidation with First and Second Allogeneic Transplants in Adults with Relapsed/Refractory B-ALL Following Response to CD19CAR T Cell Therapy

Author

Aldoss, Ibrahim, Shan, Haoyue, Yang, Dongyun, Clark, Mary C., Al Malki, Monzr, Aribi, Ahmed, Agrawal, Vaibhav, Sandhu, Karamjeet, Salhotra, Amandeep, Pourhassan, Hoda, Koller, Paul, Ali, Haris, Artz, Andrew, Karras, Nicole, Pawlowska, Anna B., Murphy, Lindsey, Palmer, Joycelynne, Stein, Anthony, Marcucci, Guido, Pullarkat, Vinod, Nakamura, Ryotaro, and Forman, Stephen J.

Published
2024
Full Text
View/download PDF

7. Outcomes of allogeneic hematopoietic cell transplantation in adults with fusions associated with Ph-like ALL

Author

Aldoss, Ibrahim, Yang, Dongyun, Tomasian, Vanina, Mokhtari, Sally, Jackson, Ryan, Gu, Zhaohui, Telatar, Milhan, Yew, Hooi, Al Malki, Monzr M., Salhotra, Amandeep, Khaled, Samer, Ali, Haris, Aribi, Ahmed, Sandhu, Karamjeet S., Mei, Matthew, Arslan, Shukaib, Koller, Paul, Artz, Andrew, Aoun, Patricia, Gu, Dongqing, Snyder, David, Stewart, Forrest M., Curtin, Peter, Stein, Anthony S., Pillai, Raju, Marcucci, Guido, Forman, Stephen J., Pullarkat, Vinod, Nakamura, Ryotaro, and Afkhami, Michelle

Published
2022
Full Text
View/download PDF

10. Toxicities associated with tyrosine kinase inhibitor maintenance following allogeneic hematopoietic cell transplantation in Philadelphia chromosome‐positive acute lymphoblastic leukemia.

Author

Othman, Tamer, Koller, Paul, Tsai, Ni‐Chun, Yang, Dongyun, Pourhassan, Hoda, Agrawal, Vaibhav, Ngo, Dat, Chen, Jason, Farol, Leonardo, Spielberger, Ricardo, Sahebi, Firoozeh, Al Malki, Monzr M., Cai, Ji‐Lian, Sandhu, Karamjeet S., Mansour, Joshua, Salhotra, Amandeep, Ali, Haris, Aribi, Ahmed, Arslan, Shukaib, and Marcucci, Guido

Published
2024
Full Text
View/download PDF

11. Flotetuzumab as a salvage immunotherapy in advanced CD123-positive hematological malignancies, a phase 1 pilot study.

Author

Aldoss, Ibrahim, Zhang, Jianying, Robbins, Marjorie, Song, Joo, Al Malki, Monzr M., Otoukesh, Salman, Sandhu, Karamjeet, Agrawal, Vaibhav, Herrera, Alex F., Popplewell, Leslie L., Ghoda, Lucy, Stein, Anthony, Marcucci, Guido, Forman, Stephen, and Pullarkat, Vinod

Subjects
HEMATOLOGIC malignancies, HODGKIN'S disease, CYTOKINE release syndrome, IMMUNOTHERAPY, CANCER remission
Abstract

CD123 "expression" is common in hematological malignancies, including acute lymphoblastic leukemia (ALL). Flotetuzumab is a novel, investigational CD3/CD123 DART®. We conducted a phase 1 study evaluating safety and efficacy of flotetuzumab in relapsed/refractory ALL (Cohort A) and other advanced CD123-positive hematological malignancies (excluding myeloid malignancies) (cohort B). Thirteen patients (9 in Cohort A and 4 in Cohort B) were treated at dose level 1 (500 ng/kg/day) before early closure due to discontinuation of drug development by sponsor. Two dose limiting toxicities (Grade 4 thrombocytopenia and neutropenia) occurred in one patient in Cohort B. Cytokine release syndrome occurred in most patients (85%), all being grade ≤2. Responses only occurred in Cohort B, with a partial response in one patient with Hodgkin's lymphoma and morphological complete remission in the bone marrow in one patient with blastic plasmacytoid dendritic cell neoplasm. In conclusion, flotetuzumab had a manageable safety profile in advanced CD123-positive hematological malignancies. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

12. Outcomes following allogeneic hematopoietic cell transplantation relapse in Philadelphia chromosome‐positive acute lymphoblastic leukemia.

Author

Othman, Tamer, Li, Shanpeng, Zhang, Jianying, Pourhassan, Hoda, Agrawal, Vaibhav, Ngo, Dat, Chen, Jason, Farol, Leonardo, Sahebi, Firoozeh, Sandhu, Karamjeet, Spielberger, Ricardo, Marcucci, Guido, Forman, Stephen J., Stein, Anthony S., Nakamura, Ryotaro, Pullarkat, Vinod, Mei, Matthew, Aldoss, Ibrahim, and Koller, Paul

Published
2024
Full Text
View/download PDF

13. Therapy‐related acute lymphoblastic leukaemia in women with antecedent breast cancer.

Author

Pourhassan, Hoda, Zhang, Jianying, Tinajero, Jose, Pullarkat, Vinod, Agrawal, Vaibhav, Koller, Paul, Al Malki, Monzr, Aribi, Ahmed, Salhotra, Amandeep, Sandhu, Karamjeet, Ali, Haris, Stein, Anthony, Marcucci, Guido, Forman, Stephen, and Aldoss, Ibrahim

Subjects
LYMPHOBLASTIC leukemia, ACUTE leukemia, BREAST cancer, CARCINOGENS, PHILADELPHIA chromosome
Abstract

Summary: Therapy‐related acute lymphoblastic leukaemia (tr‐ALL) is a disease entity attributed to previous exposure to chemotherapy and/or radiation for antecedent malignancy. There is observed female predominance for tr‐ALL, likely due to high prevalence and excellent curable rate for non‐metastatic breast cancer as well as the frequent use of carcinogenic agents as part of adjuvant therapy. Here, we reviewed 37 women with diagnosis of ALL following breast cancer treatment with focus on cytogenetic categorization. Philadelphia chromosome positivity (Ph+), KMT2A alterations and other cytogenetic change groups were observed in 32%, 22% and 46% of patients respectively. Median overall survival (OS) and relapse‐free survival (RFS) were 19.4 and 12.9 months, overall while both OS and RFS were superior in tr‐ALL with Ph+ disease compared to KMT2Ar and other cytogenetics respectively. Seventeen (45.9%) patients underwent consolidative allogeneic haematopoietic cell transplantation (alloHCT) in CR1 out of which 4 (24%) relapsed following transplant. Both OS and RFS were superior in the KMT2Ar cytogenetics group following alloHCT. Ph chromosome represents the largest genetic entity of tr‐ALL following breast cancer therapy, and it may be associated with superior survival outcomes while KMT2Ar may be associated with poorer outcomes that can perhaps be mitigated by alloHSCT. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

14. High remission rates and transition to allogeneic transplant in older patients with newly diagnosed FLT-3 mutated acute myelogenous leukemia with midostaurin plus intensive chemotherapy.

Author

Tinajero, Jose, Ngo, Dat, Zhang, Jianying, Tsai, Ni-Chun, Aribi, Ahmed, Aldoss, Ibrahim, Agrawal, Vaibhav, Arslan, Shukaib, Amanam, Idoroenyi, Pourhassan, Hoda, Sandhu, Karamjeet, Al-Malki, Monzr, Pullarkat, Vinod, Becker, Pamela, Nakamura, Ryotaro, Stein, Anthony, Marcucci, Guido, Artz, Andrew, Koller, Paul, and Salhotra, Amandeep

Subjects
ACUTE myeloid leukemia, OLDER patients
Abstract

This document presents data on the outcomes and toxicities of a treatment regimen for older adults with newly diagnosed FLT3-mutated acute myeloid leukemia (AML). The study found that the treatment approach, which included induction chemotherapy with the addition of midostaurin, resulted in a high complete remission rate and a median overall survival of 9.3 months. Additionally, a significant number of patients underwent allogeneic hematopoietic stem cell transplantation (allo-HCT) with favorable outcomes. The authors conclude that this treatment approach is feasible and effective for older adults with FLT3-mutated AML. However, the study lacked long-term follow-up and data on minimal residual disease achievement and allo-HCT outcomes. [Extracted from the article]

Published
2024
Full Text
View/download PDF

15. Use of high-dose mesna and hyperhydration leads to lower incidence of hemorrhagic cystitis after posttransplant cyclophosphamide-based allogeneic transplantation

Author

Mac, Stephanie, Ngo, Dat, Yang, Dongyun, Chen, Jason, Ali, Haris, Arslan, Shukaib, Dadwal, Sanjeet, Salhotra, Amandeep, Cao, Thai, Karras, Nicole, Aldoss, Ibrahim, Koller, Paul, Artz, Andrew, Aribi, Ahmed, Sandhu, Karamjeet, Pullarkat, Vinod, Stein, Anthony, Marcucci, Guido, Forman, Stephen J., Nakamura, Ryotaro, and Al Malki, Monzr M.

Published
2021
Full Text
View/download PDF

17. Biomarker-guided preemption of steroid-refractory graft-versus-host disease with α-1-antitrypsin

Author

Gergoudis, Stephanie C., DeFilipp, Zachariah, Özbek, Umut, Sandhu, Karamjeet S., Etra, Aaron M., Choe, Hannah K., Kitko, Carrie L., Ayuk, Francis, Aziz, Mina, Baez, Janna, Ben-David, Kaitlyn, Bunworasate, Udomsak, Gandhi, Isha, Hexner, Elizabeth O., Hogan, William J., Holler, Ernst, Kasikis, Stelios, Kowalyk, Steven M., Lin, Jung-Yi, Merli, Pietro, Morales, George, Nakamura, Ryotaro, Reshef, Ran, Rösler, Wolf, Srinagesh, Hrishikesh, Young, Rachel, Chen, Yi-Bin, Ferrara, James L.M., and Levine, John E.

Published
2020
Full Text
View/download PDF

19. Long-Term Outcomes of Allogeneic Hematopoietic Cell Transplant with Fludarabine and Melphalan Conditioning and Tacrolimus/Sirolimus as Graft-versus-Host Disease Prophylaxis in Patients with Acute Lymphoblastic Leukemia

Author

Mei, Matthew, Tsai, Ni-Chun, Mokhtari, Sally, Al Malki, Monzr M., Ali, Haris, Salhotra, Amandeep, Sandhu, Karamjeet, Khaled, Samer, Smith, Eileen, Snyder, David, Marcucci, Guido, Forman, Stephen J., Pullarkat, Vinod, Stein, Anthony, Aldoss, Ibrahim, and Nakamura, Ryotaro

Published
2020
Full Text
View/download PDF

20. Outcomes of Allogeneic Hematopoietic Cell Transplantation after Salvage Therapy with Blinatumomab in Patients with Relapsed/Refractory Acute Lymphoblastic Leukemia

Author

Salhotra, Amandeep, Yang, Dongyun, Mokhtari, Sally, Malki, Monzr M. Al, Ali, Haris, Sandhu, Karamjeet S., Aribi, Ahmed, Khaled, Samer, Mei, Matthew, Budde, Elizabeth, Snyder, David, Cao, Thai, Spielberger, Ricardo, Marcucci, Guido, Pullarkat, Vinod, Forman, Stephen J., Nakamura, Ryotaro, Stein, Anthony, and Aldoss, Ibrahim

Published
2020
Full Text
View/download PDF

21. Long-Term Outcomes of Patients with Acute Myelogenous Leukemia Treated with Myeloablative Fractionated Total Body Irradiation TBI-Based Conditioning with a Tacrolimus- and Sirolimus-Based Graft-versus-Host Disease Prophylaxis Regimen: 6-Year Follow-Up from a Single Center

Author

Salhotra, Amandeep, Hui, Susanta, Yang, Dongyun, Mokhtari, Sally, Mei, Matthew, Al Malki, Monzr M., Aldoss, Ibrahim, Ali, Haris, Sandhu, Karamjeet S., Aribi, Ahmed, Khaled, Samer, Dandapani, Savita, Peng, Kelly, Teh, Jennifer Berano, Murata-Collins, Joyce, Budde, Elizabeth, Dadwal, Sanjeet, Pullarkat, Vinod, Snyder, David, Spielberger, Ricardo, Wong, Jeffry, Armenian, Saro, Marcucci, Guido, Forman, Stephen J., Nakamura, Ryotaro, and Stein, Anthony

Published
2020
Full Text
View/download PDF

22. The MAGIC algorithm probability is a validated response biomarker of treatment of acute graft-versus-host disease

Author

Srinagesh, Hrishikesh K., Özbek, Umut, Kapoor, Urvi, Ayuk, Francis, Aziz, Mina, Ben-David, Kaitlyn, Choe, Hannah K., DeFilipp, Zachariah, Etra, Aaron, Grupp, Stephan A., Hartwell, Matthew J., Hexner, Elizabeth O., Hogan, William J., Karol, Alexander B., Kasikis, Stelios, Kitko, Carrie L., Kowalyk, Steven, Lin, Jung-Yi, Major-Monfried, Hannah, Mielke, Stephan, Merli, Pietro, Morales, George, Ordemann, Rainer, Pulsipher, Michael A., Qayed, Muna, Reddy, Pavan, Reshef, Ran, Rösler, Wolf, Sandhu, Karamjeet S., Schechter, Tal, Shah, Jay, Sigel, Keith, Weber, Daniela, Wölfl, Matthias, Wudhikarn, Kitsada, Young, Rachel, Levine, John E., and Ferrara, James L.M.

Published
2019
Full Text
View/download PDF

24. Pulmonary hypertension is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation for myelofibrosis

Author

Gupta, Rohan, Jamal, Faizi, Yang, Dongyun, Chendri, Chendri, Aldoss, Ibrahim, Malki, Monzr Al, Mei, Matthew, Salhotra, Amandeep, Dobrin, Surime, Tran, Michael, Venkataraman, K., Palmer, Joycelynne, Stein, Anthony S., Sandhu, Karamjeet, Khaled, Samer, Aribi, Ahmed, Marcucci, Guido, Forman, Stephen J., Snyder, David, Nakamura, Ryotaro, Ali, Haris, and Pullarkat, Vinod

Published
2020
Full Text
View/download PDF

25. Allogeneic Hematopoietic Cell Transplantation Outcomes in Patients Carrying Isocitrate Dehydrogenase Mutations

Author

Salhotra, Amandeep, Afkhami, Michelle, Yang, Dongyun, Mokhtari, Sally, Telatar, Milhan, Gu, Dongqing, Pillai, Raju K., Weisenburger, Dennis D., Murata-Collins, Joyce, Weigel, Diana, Aoun, Patricia, Aldoss, Ibrahim, Al Malki, Monzr M., Khaled, Samer, Mei, Matthew, Ali, Haris, Aribi, Ahmed, Budde, Elizabeth, Sandhu, Karamjeet, O’Donnell, Margaret, Snyder, David, Pullarkat, Vinod, Forman, Stephen J., Marcucci, Guido, Nakamura, Ryotaro, and Stein, Anthony

Published
2019
Full Text
View/download PDF

27. Treatment of relapsed or refractory FLT-3 acute myelogenous leukemia with a triplet regimen of hypomethylating agent, venetoclax, and gilteritinib.

Author

Ngo, Dat, Tinajero, Jose, Li, Shanpeng, Palmer, Joycelynne, Pourhassan, Hoda, Aribi, Ahmed, Nakamura, Ryotaro, Stein, Anthony, Marcucci, Guido, Salhotra, Amandeep, Sandhu, Karamjeet, Pullarkat, Vinod, Ball, Brian, and Koller, Paul

Subjects
ACUTE myeloid leukemia, VENETOCLAX, HEMATOPOIETIC stem cells, STEM cell transplantation, PROTEIN-tyrosine kinases
Abstract

Relapsed or refractory (R/R) acute myeloid leukemia (AML) with FMS-like tyrosine kinase 3 (FLT3) mutations remains a difficult and hard to treat entity. Gilteritinib is a potent oral FLT-3 inhibitor that improves overall survival in R/R AML, but studies are limited in combining gilteritinib with a hypomethylating agent and venetoclax treatment backbone (HMA-VEN-GILT). Here we report our experience with HMA-VEN-GILT for 22 R/R FLT3 AML patients. HMA-VEN-GILT yielded an ORR of 77.3% (17/22), CR 4.5% (1/22), CRi 13.6% (3/22), MLFS 59.1% (13/22). Median follow-up was 10.4 months with a relapse rate of 29.4% (5/17), median time to relapse of 69 days (range 35–298 days), 6-month overall survival of 84%, and median OS of 10.1 months. Additionally, 36.4% (8/22) of patients proceeded to hematopoietic stem cell transplant. In conclusion, HMA-VEN-GILT for the treatment of R/R FLT3 AML is feasible and can be used as a bridge to allogeneic transplantation. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

28. A review of low dose interleukin-2 therapy in management of chronic graft-versus-host-disease.

Author

Salhotra, Amandeep, Falk, Leah, Park, Gabriel, Sandhu, Karamjeet, Ali, Haris, Modi, Badri, Hui, Susanta, and Nakamura, Ryotaro

Subjects
INTERLEUKIN-2, REGULATORY T cells, GRAFT versus host disease, PATIENT compliance
Abstract

Patients with chronic graft versus host disease (cGVHD) have low circulating regulatory T cells (Tregs). Interleukin-2(IL-2) is a growth factor for Tregs, and clinical trials have explored its use in cGVHD patients. Here we will discuss the biology of IL-2, its rationale for use and results of clinical trials in cGVHD. We also describe its mechanisms of action and alteration in gene expression in T-cell subsets after treatment with low dose IL-2 and photopheresis. Clinical trials using Low dose IL-2 have been done at single centers in small patient series. The majority of the clinical responses seen with IL-2 in cGVHD are classified as partial responses and efficacy as a single agent is limited. Compared to currently approved oral therapies, it has to be administered subcutaneously and requires specialized processing for compounding and storage limiting its widespread use. Its use is associated with constitutional symptoms and local injection site reactions. Local reactions can be easily managed by supportive care practices like rotation of injection sites and premeditations, constitutional symptoms resolve with, dose reduction (25–50%) allowing for continued therapy. Additional studies are needed to define optimal combination strategies with approved agents. Longer acting formulations of IL-2 that require less frequent dosing may also improve patient compliance. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

29. Melphalan-Based Reduced-Intensity Conditioning is Associated with Favorable Disease Control and Acceptable Toxicities in Patients Older Than 70 with Hematologic Malignancies Undergoing Allogeneic Hematopoietic Stem Cell Transplantation

Author

Al Malki, Monzr M., Nathwani, Nitya, Yang, Dongyun, Armenian, Saro, Dadwal, Sanjeet, Salman, Jaroslava, Mokhtari, Sally, Cao, Thai, Sandhu, Karamjeet, Rouse, Michelle, Mei, Matthew, Ali, Haris, Parker, Pablo, Alvarnas, Joseph, Smith, Eileen, Donnell, Margaret O., Marcucci, Guido, Snyder, David, Nademanee, Auayporn, Forman, Stephen J., Stein, Anthony, and Nakamura, Ryotaro

Published
2018
Full Text
View/download PDF

30. Allogeneic Hematopoietic Cell Transplantation for Adult T Cell Acute Lymphoblastic Leukemia

Author

Hamilton, Betty Ky, Rybicki, Lisa, Abounader, Donna, Adekola, Kehinde, Advani, Anjali, Aldoss, Ibrahim, Bachanova, Veronika, Bashey, Asad, Brown, Stacey, DeLima, Marcos, Devine, Steven, Flowers, Christopher R., Ganguly, Siddharth, Jagasia, Madan, Kennedy, Vanessa E., Kim, Dennis Dong Hwan, McGuirk, Joseph, Pullarkat, Vinod, Romee, Rizwan, Sandhu, Karamjeet, Smith, Melody, Ueda, Masumi, Viswabandya, Auro, Vu, Khoan, Wall, Sarah, Zeichner, Simon B., Perales, Miguel-Angel, and Majhail, Navneet S.

Published
2017
Full Text
View/download PDF

31. WT1-mutated acute myeloid leukemia is sensitive to fludarabine-based chemotherapy and conditioning regimens.

Author

Aribi, Ahmed, Salhotra, Amandeep, Afkhami, Michelle, Munteanu, Anamaria, Ali, Haris, Aldoss, Ibrahim, Otoukesh, Salman, Al Malki, Monzr M., Sandhu, Karamjeet S., Koller, Paul, Arslan, Shukaib, Stewart, Forrest, Artz, Andrew, Curtin, Peter, Ball, Brian, O'Hearn, James, Spielberger, Ricardo, Smith, Eileen, Budde, Elizabeth, and Nakamura, Ryotaro

Subjects
ACUTE myeloid leukemia, STEM cell transplantation, CANCER chemotherapy, FLUDARABINE
Abstract

We conducted a retrospective analysis of WT1-mutated acute myeloid leukemia (AML) patients who underwent allogeneic stem cell transplant. Thirty-seven patients with WT1-mutated AML were identified. Primary induction failure (40%) and early relapse rate (18%) after idarubicin/cytarabine (7 + 3) chemotherapy were observed. All patients with induction failure subsequently achieved CR with additional chemotherapy. There was no significant difference between outcomes after myeloablative vs. reduced intensity (Fludarabine/Melphalan [Flu/Mel]) conditioning regimens. RFS but not OS was significantly better in patients who received FLAG-IDA prior to transplant and/or a fludarabine-containing conditioning. In an independent ex vivo study, WT1-mutated AML samples exhibited greater sensitivity to fludarabine (p = 0.026) and melphalan (p = 0.0005) than non-WT1-mutated AML samples while there was no difference between sensitivity to cytarabine. Our data favor using a fludarabine-based induction for AML with WT1 mutation instead of 7 + 3. Fludarabine conditioning regimens for alloHCT showed better RFS but not OS. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

32. Allogeneic Hematopoietic Cell Transplantation for Relapsed and Refractory Philadelphia Negative B Cell ALL in the Era of Novel Salvage Therapies

Author

Aldoss, Ibrahim, Yang, Dongyun, Malki, Monzr M. Al, Mei, Matthew, Mokhtari, Sally, Artz, Andrew, Cao, Thai, Salhotra, Amandeep, Ali, Haris, Aribi, Ahmed, Khaled, Samer, Arslan, Shukaib, Sandhu, Karamjeet, Koller, Paul, Mansour, Joshua, Spielberger, Ricardo, Stein, Anthony, Snyder, David, Marcucci, Guido, Forman, Stephen J., Nakamura, Ryotaro, and Pullarkat, Vinod

Published
2021
Full Text
View/download PDF

33. ALL-502 Obecabtagene Autoleucel (Obe-Cel) for Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Impact of Chimeric Antigen Receptor T-Cell (CAR T) and Tumor Burden–Guided Dosing in the FELIX Phase 1b/2 Study

Author

Jabbour, Elias, Sandhu, Karamjeet S., Shaughnessy, Paul, Logan, Aaron C., Abedi, Mehrdad, Shah, Bijal D., Bishop, Michael R., Park, Jae H., DeAngelo, Daniel J., Raymond, Meera, Hu, Yanqing, Lao-Sirieix, Pierre, Saxena, Kapil, Brugger, Wolfram, Pule, Martin A., Shang, Justin, and Roddie, Claire

Published
2024
Full Text
View/download PDF

34. Obecabtagene Autoleucel (Obe-Cel) for Relapsed/Refractory Adult B-Cell Acute Lymphoblastic Leukemia (R/R B-ALL): Impact of Chimeric Antigen Receptor T-Cell (CAR T) and Tumor Burden–Guided Dosing in the FELIX Phase 1b/2 Study

Author

Jabbour, Elias, Sandhu, Karamjeet S., Shaughnessy, Paul, Logan, Aaron C., Abedi, Mehrdad, Shah, Bijal D., Bishop, Michael R., Park, Jae H., DeAngelo, Daniel J., Raymond, Meera, Hu, Yanqing, Lao-Sirieix, Pierre, Saxena, Kapil, Brugger, Wolfram, Pule, Martin A., Shang, Justin, and Roddie, Claire

Published
2024
Full Text
View/download PDF

35. High response rates and transition to transplant after novel targeted and cellular therapies in adults with relapsed/refractory acute lymphoblastic leukemia with Philadelphia‐like fusions.

Author

Aldoss, Ibrahim, Afkhami, Michelle, Yang, Dongyun, Gu, Zhaohui, Mokhtari, Sally, Shahani, Shilpa, Pourhassan, Hoda, Agrawal, Vaibhav, Koller, Paul, Arslan, Shukaib, Tomasian, Vanina, Al Malki, Monzr M., Artz, Andrew, Salhotra, Amandeep, Ali, Haris, Aribi, Ahmed, Sandhu, Karamjeet S., Ball, Brian, Otoukesh, Salman, and Amanam, Idoroenyi

Published
2023
Full Text
View/download PDF

36. Use of monoclonal antibody therapy in hematologic patients with mild-to-moderate COVID-19: A retrospective single-center experience.

Author

Amanam, Idoroenyi, Janny Yao, Puing, Alfredo, Ni-Chun Tsai, Samuels, Diana, Dat Ngo, Stephanie Ho, Ali, Haris, Aribi, Ahmed, Arslan, Shukaib, Artz, Andrew, Myo Htut, Koller, Paul, Salhotra, Amandeep, Sandhu, Karamjeet, Liana Nikolaenko, Pawlowska, Anna, Shouse, Geoffrey, Stein, Anthony, and Marcucci, Guido

Subjects
COVID-19, MONOCLONAL antibodies, VIRAL shedding, HEMATOLOGIC malignancies
Abstract

Introduction: In November 2020, the FDA issued an emergency use authorization (EUA) for monoclonal antibody (mAb) therapy in patients with mild-to-moderate COVID-19 at high risk for disease progression. Methods: We retrospectively reviewed 38 adult hematology patients who received mAbs from 11/2020 to 2/2021. Results: Thirty (79%) patients received bamlanivimab and 8 (21%) casirivimab-imdevimab. Four (11%) patients were hospitalized due to COVID-19, two (5%) progressed to severe disease and one patient (3%) died within 30 days from COVID-19 disease. Most patients (n = 34, 89%) ultimately tested negative for SARS-CoV-2, with 34% (n = 13) clearing the virus within 14 days after mAb infusion. The median time to clearance of viral shedding was 25.5 days (range: 7-138). After mAb infusion, most patients with hematological malignancies (HM) (n = 10/15; 67%) resumed therapy for underlying disease with a median delay of 21.5 days (range: 12-42). We observed a significant difference in hospitalization among patients who received a HCT versus non-HCT (0% n = 0/26 and 36% n = 4/11, respectively; p < 0.01). Conclusions: This study demonstrates that SARS-CoV-2 specific mAb was safe and may reduce hospitalization compared to what is reported in malignant hematology patients at high risk for disease progression. Our HCT cohort patients had less hospitalization rate compared with HM cohort patients. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

37. Novel Salvage Therapies Are Highly Effective in Adults with Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL) with Philadelphia (Ph)-like Fusions

Author

Aldoss, Ibrahim, Yang, Dongyun, Afkhami, Michelle, Gu, Zhaohui, Mokhtari, Sally, Shahani, Shilpa, Agrawal, Vaibhav, Pourhassan, Hoda, Koller, Paul B., Tomasian, Vanina, Telatar, Milhan, Al Malki, Monzr M., Salhotra, Amandeep, Ali, Haris, Aribi, Ahmed, Sandhu, Karamjeet S., Arslan, Shukaib, Ball, Brian J, Otoukesh, Salman, Amanam, Idoroenyi, Artz, Andrew S., Becker, Pamela S., Stewart, Forrest M., Curtin, Peter T., Pillai, Raju, Smith, Eileen P., Marcucci, Guido, Stein, Anthony S., Forman, Stephen J, Nakamura, Ryotaro, and Pullarkat, Vinod A.

Published
2022
Full Text
View/download PDF

38. Outcome of Patients Undergoing Hematopoietic Cell Transplantation for TP53-Mutated Acute Leukemias and MDS: Effect of Conditioning and GvHD Prophylaxis Regimens Intensity

Author

Desai, Amrita, Sandhu, Karamjeet S., Koller, Paul B., Yang, Dongyun, Ball, Brian J, Mokhtari, Sally, Blackmon, Amanda, Otoukesh, Salman, Arslan, Shukaib, Amanam, Idoroenyi, Salhotra, Amandeep, Aribi, Ahmed, Aldoss, Ibrahim, Artz, Andrew S., Ali, Haris, Stein, Anthony S., Marcucci, Guido, Forman, Stephen J, Nakamura, Ryotaro, Afkhami, Michelle, and Al Malki, Monzr M.

Published
2022
Full Text
View/download PDF

39. Outcomes Post-Allogeneic Hematopoietic Cell Transplantation Relapse in Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia

Author

Othman, Tamer, Aldoss, Ibrahim, Tsai, Ni-Chun, Pourhassan, Hoda, Agrawal, Vaibhav, Otoukesh, Salman, Amanam, Idoroenyi, Ngo, Dat, Chen, Jason, Al Malki, Monzr M., Salhotra, Amandeep, Ali, Haris, Aribi, Ahmed, Sandhu, Karamjeet S., Arslan, Shukaib, Ball, Brian J, Stewart, Forrest M., Curtin, Peter T., Artz, Andrew S., Snyder, David S, Marcucci, Guido, Forman, Stephen J, Stein, Anthony S., Nakamura, Ryotaro, Pullarkat, Vinod A., Mei, Matthew, and Koller, Paul B.

Published
2022
Full Text
View/download PDF

40. Phase IIa Study of Adding Itacitinib to Tacrolimus/Sirolimus Gvhd Prophylaxis after Fludarabine/Melphalan-Based Conditioning Hematopoietic Cell Transplantation for Acute Leukemias, Myelodysplastic Syndrome, or Myelofibrosis

Author

Ali, Haris, Yang, Dongyun, Mokhtari, Sally, Synold, Timothy, Amanam, Idoroenyi, Artz, Andrew S., Curtin, Peter T., Sandhu, Karamjeet S., Stein, Anthony S., Arslan, Shukaib, Otoukesh, Salman, Sahebi, Firoozeh, Mansour, Joshua, Koller, Paul B., Salhotra, Amandeep, Aldoss, Ibrahim, Pullarkat, Vinod A., Ball, Brian J, Forman, Stephen J, Marcucci, Guido, Al Malki, Monzr M., and Nakamura, Ryotaro

Published
2022
Full Text
View/download PDF

41. Multicenter Pilot Clinical Trial of Enasidenib As Maintenance Therapy after Allogeneic Hematopoietic Cell Transplantation in Patients with Acute Myeloid Leukemia (AML) Carrying IDH2 Mutations

Author

Salhotra, Amandeep, Bejanyan, Nelli, Yang, Dongyun, Mokhtari, Sally, Al Malki, Monzr M., Sandhu, Karamjeet S., Faramand, Rawan, Aldoss, Ibrahim, Artz, Andrew S., Aribi, Ahmed, Elmariah, Hany, Sahebi, Firoozeh, Mansour, Joshua, Ball, Brian J, Agrawal, Vaibhav, Li, Ling, Pullarkat, Vinod A., Forman, Stephen J, Marcucci, Guido, Nakamura, Ryotaro, and Stein, Anthony S.

Published
2022
Full Text
View/download PDF

42. A critical review of belumosudil in adult and pediatric patients with chronic graft-versus-host disease.

Author

Salhotra, Amandeep, Sandhu, Karamjeet, O'Hearn, James, Ali, Haris, Nakamura, Ryotaro, and Modi, Badri G

Subjects
GRAFT versus host disease, CHILD patients, CHRONICALLY ill, HEMATOPOIETIC stem cell transplantation, T helper cells
Abstract

Chronic graft-versus-host disease (cGVHD) is a complication of allogeneic hematopoietic cell transplantation (allo-HCT) and is the main cause of late non-relapse mortality (NRM). Three new agents are now approved to treat cGVHD, of which belumosudil has a unique and dual mechanism of action of i) targeting the Rho-GTPase-associated coiled-coil kinase 2 (ROCK2) in T helper follicular cells (TFH) and TH17 cells, this results in downregulation of proinflammatory cytokines (interleukin −21 and 17), the former in a STAT3-dependent mechanism, ii) inhibition of tissue fibrosis by targeting stress-induced polymerization of G-actin fibrils by inhibiting the Rho-ROCK-MRTF pathway. In this review we describe the epidemiology of cGVHD, its cardinal symptoms, preventive and therapeutic options, including second-line approved therapies in the United States (US). Clinical trial data that led to approval of belumosudil is discussed, in addition to the clinical scenarios in which the approved drugs may be most applicable. Belumosudil is approved for treatment of adult and pediatric patients ≥ 12 years with cGVHD after failing two lines of therapy based on results of the ROCKstar study that showed high overall response rates (ORR), favorable adverse effect profiles, and low rates of severe infections. With the availability of three new agents for treatment of cGVHD, treating physicians have more therapeutic options for patients and have additional options of development new clinical trials using a combination of recently approved drugs. [ABSTRACT FROM AUTHOR]

Published
2023
Full Text
View/download PDF

43. Eculizumab Treatment Outcomes in Patients with Allogeneic Hematopoietic Cell Transplant (alloHCT)-Associated Thrombotic Microangiopathy (TA-TMA): A Retrospective Single-Center Experience

Author

Samara, Yazeed, Yao, Janny, Tsai, Ni-Chun, Mokhtari, Sally, Aldoss, Ibrahim, Ali, Haris, Sandhu, Karamjeet S., Salhotra, Amandeep, Stein, Anthony S., Arslan, Shukaib, Aribi, Ahmed, Borogovac, Azra, Malki, Monzr M. Al, Blackmon, Amanda, Otoukesh, Salman, Amanam, Idoroenyi, Artz, Andrew S., Curtin, Peter, Pourhassan, Hoda, Koller, Paul, Ball, Brian, Agrawal, Vaibhav, Spielberger, Ricardo, Becker, Pamela S., Stewart, F. Marc, Smith, Eileen, Marcucci, Guido, Forman, Stephen J., Pullarkat, Vinod, and Nakamura, Ryotaro

Published
2024
Full Text
View/download PDF

44. Phase 1 Trial Investigating the Safety and Tolerability of Leflunomide in Patients with Steroid-Dependent Chronic Graft-Versus-Host Disease (cGVHD) after Allogeneic Hematopoietic Cell Transplant (alloHCT)

Author

Salhotra, Amandeep, Yang, Dongyun, Mokhtari, Sally, Modi, Badri, Al Malki, Monzr M., Ali, Haris, Amanam, Idoroenyi, Karras, Nicole, Sandhu, Karamjeet S., Aribi, Ahmed, Otoukesh, Salman, Artz, Andrew S., Marcucci, Guido, Forman, Stephen J., Smith, Eileen, Zeng, Defu, Rosen, Steven, and Nakamura, Ryotaro

Published
2024
Full Text
View/download PDF

46. Multicenter Pilot Clinical Trial of Enasidenib As Maintenance Therapy after Allogeneic Hematopoietic Cell Transplantation (alloHCT) in Patients with Acute Myeloid Leukemia (AML) Carrying IDH2 Mutations

Author

Salhotra, Amandeep, Bejanyan, Nelli, Yang, Dongyun, Mokhtari, Sally, Al Malki, Monzr M., Sandhu, Karamjeet S., Faramand, Rawan G, Aldoss, Ibrahim, Artz, Andrew S., Aribi, Ahmed, Elmariah, Hany, Sahebi, Firoozeh, Mansour, Joshua, Ball, Brian, Agrawal, Vaibhav, Li, Ling, Pullarkat, Vinod, Forman, Stephen J., Marcucci, Guido, Stein, Anthony S., and Nakamura, Ryotaro

Published
2024
Full Text
View/download PDF

47. Clinical experience with venetoclax and hypomethylating agents (HMA) in patients with newly diagnosed and relapsed or refractory KMT2A-Rearranged acute myeloid leukemia (AML).

Author

Ball, Brian J., Arslan, Shukaib, Koller, Paul, Ngo, Dat, Afkhami, Michelle, Salhotra, Amandeep, Al-Malki, Monzr, Aribi, Ahmed, Ali, Haris, Sandhu, Karamjeet, Otoukesh, Salman, Amanam, Idoroenyi, Pourhassan, Hoda, Artz, Andrew, Curtin, Peter, Stein, Anthony, Nakamura, Ryotaro, Marcucci, Guido, Smith, Eileen, and Pullarkat, Vinod

Subjects
ACUTE myeloid leukemia, VENETOCLAX
Abstract

Rearrangements of I lysine [K] methyltransferase 2 A i ( I KMT2A i ) gene, previously known as the I MLL i gene, occur in 3 to 7% of adult patients with de novo AML and are enriched in therapy-related disease, particularly after treatment with topoisomerase II inhibitors [[1]]. Response and survival of patients with KMT2A rearranged acute myeloid leukemia (AML) receiving venetoclax in combination with hypomethylating agent therapy (HMA). The inferior prognosis of KMT2A rearranged AML patients undergoing alloSCT presents an opportunity for post-transplant maintenance trials with therapies targeting KMT2A. [Extracted from the article]

Published
2022
Full Text
View/download PDF

49. POSTER: AML-408 Comparing Intensive Purine Analogues Regimens With Cladribine and Fludarabine: CLIA-Venetoclax vs FLAG-Ida-Venetoclax for Relapsed and Refractory Acute Myeloid Leukemia During a Fludarabine Shortage

Author

Tinajero, Jose, Ngo, Dat, Lee, Brian, Kim, Hoim, Aldoss, Ibrahim, Ball, Brian, Koller, Paul, Arslan, Shukaib, Pourhassan, Hoda, Otoukesh, Salman, Al Malki, Monzr, Stein, Anthony, Nakamura, Ryotaro, Sandhu, Karamjeet, and Blackmon, Amanda

Published
2023
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results